Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AQBNASDAQ:CGIXNYSE:OGENNASDAQ:ZVSA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAQBAquaBounty Technologies$0.79+4.9%$0.76$0.47▼$1.94$3.06M1.22447,241 shs749,059 shsCGIXCancer Genetics$0.19$0.26$2.11▼$17.50$792K2.722.44 million shs19,116 shsOGENOragenics$3.71-15.1%$5.15$3.12▼$75.60$2.65M0.94106,041 shs84,162 shsZVSAZyVersa Therapeutics$0.69+7.8%$0.63$0.47▼$6.30$3.29M0.741.50 million shs1.14 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAQBAquaBounty Technologies+4.95%-13.09%-3.43%+33.17%-52.64%CGIXCancer Genetics0.00%0.00%0.00%0.00%0.00%OGENOragenics-15.10%-24.75%-37.79%-51.64%-91.92%ZVSAZyVersa Therapeutics+7.81%-1.71%+31.96%-1.57%-86.34%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAQBAquaBounty Technologies0.8411 of 5 stars0.04.00.00.02.80.00.6CGIXCancer GeneticsN/AN/AN/AN/AN/AN/AN/AN/AOGENOragenics0.2856 of 5 stars0.04.00.00.00.60.80.0ZVSAZyVersa Therapeutics0.1451 of 5 stars0.02.00.00.01.10.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAQBAquaBounty Technologies 0.00N/AN/AN/ACGIXCancer Genetics 0.00N/AN/AN/AOGENOragenics 0.00N/AN/AN/AZVSAZyVersa Therapeutics 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAQBAquaBounty Technologies$2.47M1.24N/AN/A$4.10 per share0.19CGIXCancer Genetics$6.33M0.13N/AN/AN/A∞OGENOragenics$40K66.32N/AN/A$0.61 per share6.08ZVSAZyVersa TherapeuticsN/AN/AN/AN/A$3.40 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAQBAquaBounty Technologies-$149.19M-$19.05N/A∞N/A-5,842.69%-111.70%-85.47%8/5/2025 (Estimated)CGIXCancer GeneticsN/A-$2.07N/A∞N/AN/AN/AN/AN/AOGENOragenics-$20.66M-$33.63N/A∞N/AN/A-2,087.95%-486.56%N/AZVSAZyVersa Therapeutics-$9.41MN/A0.00N/AN/AN/A-109.54%-43.95%8/8/2025 (Estimated)Latest CGIX, AQB, OGEN, and ZVSA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025AQBAquaBounty Technologies-$0.61$0.16+$0.77$0.11$0.20 millionN/A5/12/2025Q1 2025ZVSAZyVersa Therapeutics-$0.40-$0.73-$0.33-$0.73N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAQBAquaBounty TechnologiesN/AN/AN/AN/AN/ACGIXCancer GeneticsN/AN/AN/AN/AN/AOGENOragenicsN/AN/AN/AN/AN/AZVSAZyVersa TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAQBAquaBounty TechnologiesN/A0.540.54CGIXCancer GeneticsN/AN/AN/AOGENOragenicsN/A1.931.93ZVSAZyVersa TherapeuticsN/A0.180.18Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAQBAquaBounty Technologies8.92%CGIXCancer Genetics8.92%OGENOragenics18.71%ZVSAZyVersa Therapeutics3.91%Insider OwnershipCompanyInsider OwnershipAQBAquaBounty Technologies2.20%CGIXCancer Genetics15.00%OGENOragenics10.10%ZVSAZyVersa Therapeutics0.21%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAQBAquaBounty Technologies1003.87 million3.78 millionNo DataCGIXCancer GeneticsN/A4.09 millionN/ANot OptionableOGENOragenics5715,00010.98 millionN/AZVSAZyVersa Therapeutics24.77 million4.76 millionNot OptionableCGIX, AQB, OGEN, and ZVSA HeadlinesRecent News About These CompaniesZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Sees Large Growth in Short InterestJune 18 at 3:19 AM | americanbankingnews.comContrasting Schrödinger (NASDAQ:SDGR) & ZyVersa Therapeutics (NASDAQ:ZVSA)June 16 at 1:21 AM | americanbankingnews.comZyVersa Therapeutics (NASDAQ:ZVSA) Raised to "Sell" at Wall Street ZenJune 15, 2025 | americanbankingnews.comReviewing ZyVersa Therapeutics (NASDAQ:ZVSA) and Belite Bio (NASDAQ:BLTE)June 13, 2025 | americanbankingnews.comZyVersa Therapeutics Highlights Published Study Reinforcing That Microglia-driven Inflammation Is Pivotal in Development of Parkinson’s and Alzheimer’s DiseasesMay 22, 2025 | seekingalpha.comZyVersa Therapeutics Highlights New Research Supporting Inflammasome ASC Inhibitor IC 100 as Potential Treatment for Parkinson's DiseaseMay 20, 2025 | quiverquant.comZyVersa Therapeutics Highlights Published Study Reinforcing That Microglia-driven Inflammation Is Pivotal in Development of Parkinson's and Alzheimer's DiseasesMay 20, 2025 | globenewswire.comZyVersa Therapeutics, Inc. Provides Pipeline and Financial Update: Advances in Clinical Trials for VAR 200 and IC 100May 14, 2025 | nasdaq.comZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline ProgressMay 12, 2025 | globenewswire.comZyVersa progresses with obesity inflammation treatmentMay 9, 2025 | uk.investing.comZyVersa Unveils Groundbreaking Potential of Inflammasome Inhibitors in Combination with GLP-1 Agonists to Address Unmet Medical Needs of People Living with Obesity; Provides R&D UpdateMay 7, 2025 | globenewswire.comZyVersa Therapeutics Announces Published Data Showing Inflammasome ASC Inhibitor IC 100 Decreases Microglial Inflammasome Activation and Alpha-Synuclein That Contribute to ...April 29, 2025 | msn.comZyVersa Therapeutics Announces Published Data Showing Inflammasome ASC Inhibitor IC 100 Decreases Microglial Inflammasome Activation and Alpha-Synuclein That Contribute to Neurodegeneration in Parkinson's DiseaseApril 29, 2025 | globenewswire.comZyVersa Therapeutics CEO provides update on inflammasome ASC inhibitor IC 100April 25, 2025 | markets.businessinsider.comZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative R&D Trends for Inflammasome Inhibitors, and Provides Update on Inflammasome ASC Inhibitor IC 100's Development StatusApril 24, 2025 | globenewswire.comZyVersa Therapeutics CEO Issues Shareholder Letter on PARASOL Recommendations Expected to Reduce Drug Development Barrier for Rare Kidney Disease, Focal Segmental ...April 10, 2025 | seekingalpha.comWhy ZyVersa Therapeutics, Inc. (ZVSA) Went Down On Thursday?April 10, 2025 | msn.comWhy ZyVersa Therapeutics, Inc. (ZVSA) Went Down On Thursday?April 10, 2025 | insidermonkey.comZyVersa Therapeutics CEO Issues Shareholder Letter on PARASOL Recommendations Expected to Reduce Drug Development Barrier for Rare Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS)April 8, 2025 | globenewswire.comZyVersa Therapeutics files to sell 4.21M shares of common stock for holdersApril 5, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCGIX, AQB, OGEN, and ZVSA Company DescriptionsAquaBounty Technologies NASDAQ:AQB$0.79 +0.04 (+4.95%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$0.78 -0.01 (-1.50%) As of 06/18/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AquaBounty Technologies, Inc., a biotechnology company, operates in the aquaculture industry in the United States and Canada. The company engages in genetic, genomic, and fish health and nutrition research activities. It also operates salmon farms using proprietary technology. In addition, the company offers AquAdvantage Salmon, a genetically engineered Atlantic salmon for human consumption; and sells conventional Atlantic salmon, salmon eggs, fry, and byproducts. The company was formerly known as Aqua Bounty Farms, Inc. and changed its name to AquaBounty Technologies, Inc. in June 2004. AquaBounty Technologies, Inc. was incorporated in 1991 and is headquartered in Harvard, Massachusetts.Cancer Genetics NASDAQ:CGIXVyant Bio, Inc. is a biotechnology company, which engages in drug discovery for complex neurodevelopmental and neurodegenerative disorders. The firm's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Its programs are focused on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome, CDKL5 Deficiency Disorders, and familial Parkinson's Disease. The company was founded on April 8, 1999 and is headquartered in Cherry Hill, NJ.Oragenics NYSE:OGEN$3.71 -0.66 (-15.10%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$3.88 +0.17 (+4.58%) As of 06/18/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.ZyVersa Therapeutics NASDAQ:ZVSA$0.69 +0.05 (+7.81%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$0.67 -0.02 (-2.32%) As of 06/18/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. ZyVersa Therapeutics, Inc. was founded in 2014 and is headquartered in Weston, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
